Adjuvant topical therapy in psoriasis
A.L. Bakulev, S.S. Kravchenya, I.A. Igonina, E.M. Galkina, S.R. Utz
Saratov State Medical University named after V.I. Razumovsky
Aim: to evaluate Cetaphil® Restoraderm™ use effectiveness in complex treatment of patients suffering from moderate-to-severe psoriasis.
Patients and Methods: 60 adult patients of both sexes with the moderate-to-severe psoriasis were examined in a phase of dermatosis progression. Indices PASI, DLQI, indices of itch intensity, as well as greasiness, moisture and elasticity of the skin were evaluated in these patients. In a composition of complex therapy with methotrexate and topical glucocorticosteroid (tGCS), the cosmetic product Cetaphil® Restoraderm™ — skin regenerating moisturizing lotion — was additionally used by the patients.
Results and Discussion: inclusion of the moisturizing cosmetic product Cetaphil® Restoraderm™ in the complex therapy resulted in earlier stabilization and regression of the psoriatic process, as well as in improving quality of life and helped to reduce skin dryness, normalize skin moisture and elasticity. By the 14th day of the therapy, positive dynamics of the psoriatic process was observed in all groups — a decrease in the PASI index (p <0.05), the most pronounced in patients who used the tGCS and Cetaphil® Restoraderm™ throughout the course of therapy. At the end of the therapy, similar data was obtained in patients who used betamethasone dipropionate for entire 28 days, and in patients treated from 14-day to 28-day with the tGCS and moisturizing cosmetic product Cetaphil® Restoraderm™.
Conclusions: cytostatic therapy with combined use of the corticosteroids and moisturizing cosmetic agent contributes to onset of an earlier effect and is able to significantly shorten the treatment period for the patients suffering from psoriasis. The inclusion of cosmetic product Cetaphil® Restoraderm™ — skin regenerating moisturizing lotion — in the daily care in the patients with moderate-to-severe plaque psoriasis during the phase of dermatosis progression contributes to optimization of the therapy and also has a pronounced seborrhagulatory, elastogenic and moisturizing effect.
Key words: psoriasis, adjuvant therapy, effectiveness, safety, Cetaphil® Restoraderm™.
For citation: Bakulev A.L., Kravchenya S.S., Igonina I.A. et al. Adjuvant topical therapy in psoriasis // RMJ. Medical Review. 2018. № 5. P. 55–59.
References
1. Feldman S.R. Disease burden and trea™ent adherence in psoriasis patients // Cutis 2013. Vol. 92. P.258–263.
2. Nast A., Boehncke W.H., Mrowietz U. et al. S3 — Guidelines on the trea™ent of psoriasis vulgaris (English version). Update // J Dtsch Dermatol Ges. 2012. Vol. 10 (Suppl. 2). S.1–95.
3. Menter А., Korman N.J., Elmets C.A. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis // J Am Acad Dermatol 2011. Vol. 65. P.137–174.
4. Федеральные клинические рекомендации по ведению больных псориазом. Российское общество дерматовенерологов и косметологов . М., 2015. 768 с. [Federal’nyye klinicheskiye rekomendatsii po vedeniyu bol’nykh psoriazom. Rossiyskoye obshchestvo dermatovenerologov i kosmetologov. M., 2015. 768 s. (in Russian)].
5. Мордовцев В.Н. Псориаз // Кожные и венерические болезни / под ред. Ю.К. Скрипкина. М.: Медицина, 1995. Т.2. C.179–230 [Mordovtsev V.N. Psoriaz // Kozhnyye i venericheskiye bolezni / рod red. Yu.K. Skripkina. M.: Meditsina, 1995. T. 2. S.179–230 (in Russian)].
6. Руководство по дерматокосметологии / под ред. Е.Р. Аравийской, Е.В. Cоколовского. СПб.: Фолиант, 2008. 632 с. [Rukovodstvo po dermatokosmetologii / рod red. Ye.R. Araviyskoy, Ye.V. Cokolovskogo. SPb.: Foliant, 2008. 632 s. (in Russian)].
7. Fluhr J.W., Cavallotti C., Berardescu E. Epidermal barrier disorders in dermatoses // Clin Dermatol. 2008. Vol. 26(4). P.380–386.
8. Schmuth M., Blunder S., Dubrac S. et al. Epidermal barrier in hereditary ichthyoses, atopic dermatitis, and psoriasis // J Dtsch Dermatol Ges. 2015. Vol. 13(11). P. 1119–1123.
9. Childhood psoriasis: often favorable outcome // Prescrire Int. 2009. Vol. 18(104). P.275.
10. Dawn A., Yosipovitch G. Treating itch in psoriasis // Dermatol Nurs. 2006. Vol. 18. P.227–233.
11. Raut A.S., Prabhu R.H., Patravale V.B. Psoriasis clinical implications and trea™ent: a review // Crit Rev Ther Drug Carrier Syst. 2013. Vol. 30. P.183–216.
12. Tidman M.J. Improving outcomes in patients with psoriasis // Practitioner. 2013. Vol. 257(1757). P.27–30.
13. Berne B., Blom I., Spångberg S. Enhanced response of psoriasis to UVB therapy after pretrea™ent with a lubricating base. A single-blind controlled study // Acta Derm Venereol. 1990. Vol. 70. P.474–477.
14. Boyvat A., Erdi H., Birol A., Gurgey E. Interaction of commonly used emollients with photochemotherapy // Photodermatol Photoimmunol Photomed. 2000. Vol. 16. P.156–160.
15. Finlay A. Emollients as adjuvant therapy for psoriasis // J Dermatol Treat. 1997. Vol. 8 (Suppl. 1). P.25–27.
16. Simpson E., Trookman N.S., Rizer R.L. et al. Safety and Tolerability of a Body Wash and Moisturizer when Applied to Infants and Toddlers with a History of Atopic Dermatitis: Results from an Open-Label Study // Pediatr Dermatol. 2012. Vol. 29(5). P.590–597.
17. Del Rosso J.Q., Kircik L.H. The integration of physiologically-targeted skin care in the management of atopic dermatitis: focus on the use of a cleanser and moisturizer system incorporating a ceramide precursor, filaggrin degradation products, and specific «skin-barrier-friendly» excipients // J Drugs Dermatol. 2013. Vol. 12(7). P.85–91.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
